Company Financials
For the quarter ended 30-09-2019, the company has reported consolidated sales of Rs 4800.80 crore, up 24.90% from last quarter sales of Rs 3843.60 crore and up 30.22 % from last year same quarter sales of Rs 3686.60 crore. The company has reported net profit after tax of Rs 1095.10 crore in the latest quarter.
The company’s top management includes Dr.Bruce L A Carter, Mr.Allan Oberman, Mr.Bharat N Doshi, Mr.G V Prasad, Mr.K Satish Reddy, Mr.Leo Puri, Mr.Prasad R Menon, Mr.Sridar Iyengar, Ms.Kalpana Morparia, Ms.Shikha Sharma. Company has S R Batliboi & Associates LLP as its auditors. As on 30-09-2019, the company has a total of 166,145,748 shares outstanding.
Investment Rationale
Amneal is the first generic company to receive approval for a generic version of Nuvaring, said Nomura. Dr Reddy’s and Teva are the other known filers, it said. Amneal will have first-mover advantage; hence, the upside for Dr Reddy’s is likely to be curtailed to an extent, it said.
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Subscribe to The Economic Times Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Subscribe to The Economic Times Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price